Skip to content

Morfeas Koumas

3 papers in the library · 14 citations · publishing 2025-2026

Papers

Sort Most recent Most cited

Adjunctive ketamine for affective symptoms, craving, and relapse prevention in opioid use disorder: protocol for a randomised, double-blind, placebo-controlled clinical trial

BMC Psychiatry October 16, 2026 Morfeas Koumas, Markos Apostolakis, Evanthia Bella et al.

Abstract Background Opioid use disorder (OUD) is a chronic relapsing condition associated with substantial mortality. Although medications for opioid use disorder (MOUD) can be effective in reducing opioid use and improving treatment outcomes, relapse to drug use remains common, highlighting the need for adjunctive interventions that address relapse-relevant symptoms not fully targeted by MOUD...

Selective transcriptomic recovery by ( 2R,6R )-hydroxynorketamine in opioid-abstinent mice: Machine learning identifies predictive biomarkers

bioRxiv (Cold Spring Harbor Laboratory) June 8, 2025 Anna Onisiforou, Morfeas Koumas, Andria Michael et al. preprint

Abstract Background Opioid abstinence induces persistent emotional disturbances and widespread neuroplastic changes, in areas of the brain including the hippocampus. Although ketamine and its metabolite ( 2R,6R )-hydroxynorketamine (HNK) show potential in reversing opioid abstinence-related deficits in rodents, the molecular mechanisms underlying their efficacy remain poorly understood. Methods...

DOI: 10.1101/2025.06.04.657935 (opens in new tab) Full text (opens in new tab) Transcriptome Μ-opioid receptor Endocrinology Pharmacology +1

Ketamine and Hydroxynorketamine as Novel Pharmacotherapies for the Treatment of Opioid Use Disorders.

Biological Psychiatry March 15, 2025 Anna Onisiforou, Andria Michael, Markos Apostolakis et al. 14 citations

Opioid use disorder (OUD) has reached epidemic proportions, with many countries facing high levels of opioid use and related fatalities. Although currently prescribed medications for OUD are considered lifesaving, they inadequately address negative affect and cognitive impairment, resulting in high relapse rates to nonmedical opioid use even years after drug cessation (protracted abstinence)....

DOI: 10.1016/j.biopsych.2024.09.008 (opens in new tab) Full text (opens in new tab) Hydroxynorketamine Opioid crisis Opioid use disorders Relapse +4